Thomas Meier Appointed as New CEO of Medios AG

The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board with effect from February 1, 2026, and designated him the new Chief Executive Officer of the Company. This leadership transition marks a significant moment for Medios AG as it positions itself for future growth in the competitive European pharmaceutical landscape. Meier succeeds Matthias Gaertner, who will remain in office until December 31, 2025, concluding a ten-year tenure that saw substantial company development.

Thomas Meier brings substantial international experience to Medios AG, having served as CEO of Swiss CDMO company Bachem Holding AG since 2020. His background includes previous roles as Chief Operations Officer on the Executive Board of Bachem and as Head of Manufacturing at Peninsula Laboratories in San Carlos, California, from 2001 to 2004. This diverse experience across different pharmaceutical sectors and geographic markets positions him well to lead Medios through its next phase of development.

Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized the strategic importance of this appointment, stating that Meier brings international leadership experience with a strong track record of capital-efficient, profitable growth. The Supervisory Board expressed confidence that Meier's entrepreneurial spirit, expertise and leadership will contribute significantly to achieving the company's ambitious goals and sustainably increasing value for shareholders, partners, and customers. Simultaneously, the Board extended sincere thanks to outgoing CEO Matthias Gaertner for his outstanding work and great commitment over the past decade, acknowledging his decisive influence on Medios' growth and success.

Thomas Meier expressed enthusiasm for his new role, stating he looks forward to leading Medios into its next phase of development. He emphasized his commitment to working with Executive Board colleagues and the entire Medios team to consistently develop the successful strategy and sustainably expand Medios' position in the European Specialty Pharma market. This leadership change comes at a crucial time as Medios continues to strengthen its position as a leading provider of Specialty Pharma in Europe with locations in Germany, the Netherlands, Belgium and Spain.

The company's focus on pioneering individualized medicine aligns with broader industry trends toward personalized healthcare solutions. Medios supports key partners in the supply chain with innovative solutions and intelligent services, working to make the most innovative therapies available through partnerships with pharmacies, specialist practices and pharmaceutical companies. More information about the company's approach to individualized medicine can be found at https://app.medios.group/en/individualizedmedicine. Additional company information is available through their corporate website at https://www.medios.group.

This leadership transition represents more than just a change in executive management—it signals Medios AG's strategic commitment to sustained growth and market expansion under experienced leadership. The appointment of an internationally proven CEO with Meier's background in pharmaceutical manufacturing and development suggests the company is positioning itself for accelerated growth and enhanced competitive positioning in the European Specialty Pharma sector. The timing of this announcement, coming before key financial reporting dates including the Quarterly Statement as of September 30, 2025, indicates careful strategic planning around this leadership transition.